MEDNAX Inc (NYSE:MD) has earned a consensus rating of “Hold” from the sixteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $53.82.
Several equities analysts recently commented on the stock. Jefferies Group reissued a “hold” rating and issued a $44.00 price objective on shares of MEDNAX in a research note on Friday, November 3rd. Citigroup dropped their price objective on shares of MEDNAX from $52.00 to $47.00 and set a “neutral” rating for the company in a research note on Friday, November 3rd. KeyCorp raised shares of MEDNAX from a “sector weight” rating to an “overweight” rating and set a $51.00 price objective for the company in a research note on Sunday, September 17th. BMO Capital Markets began coverage on shares of MEDNAX in a research note on Monday, October 16th. They set a “market perform” rating and a $46.00 price target for the company. Finally, Robert W. Baird raised their price target on shares of MEDNAX from $47.00 to $48.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd.
Shares of MEDNAX (MD) traded up $0.77 during trading on Monday, hitting $54.17. 657,063 shares of the stock were exchanged, compared to its average volume of 932,083. MEDNAX has a 12 month low of $40.56 and a 12 month high of $72.13. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.37 and a current ratio of 1.37. The company has a market cap of $4,990.00, a P/E ratio of 19.21, a PEG ratio of 1.64 and a beta of 0.39.
MEDNAX (NYSE:MD) last issued its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.87. The company had revenue of $868.95 million during the quarter, compared to the consensus estimate of $864.78 million. MEDNAX had a net margin of 7.76% and a return on equity of 10.80%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.09 EPS. equities analysts predict that MEDNAX will post 3.1 earnings per share for the current year.
In other news, insider John C. Pepia sold 3,000 shares of the stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total transaction of $154,740.00. Following the completion of the sale, the insider now directly owns 35,569 shares in the company, valued at $1,834,649.02. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Cesar L. Alvarez sold 10,668 shares of the stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the sale, the director now owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Pacer Advisors Inc. grew its holdings in MEDNAX by 8.1% in the second quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock worth $117,000 after purchasing an additional 145 shares during the period. Commonwealth Bank of Australia grew its holdings in MEDNAX by 15.3% in the second quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock worth $132,000 after purchasing an additional 293 shares during the period. Fuller & Thaler Asset Management Inc. acquired a new stake in MEDNAX in the third quarter worth $103,000. QS Investors LLC grew its holdings in MEDNAX by 0.3% in the second quarter. QS Investors LLC now owns 3,812 shares of the company’s stock worth $230,000 after purchasing an additional 12 shares during the period. Finally, BB&T Investment Services Inc. acquired a new stake in MEDNAX in the second quarter worth $243,000. Institutional investors own 98.43% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “MEDNAX Inc (MD) Receives $53.82 Consensus Price Target from Brokerages” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/11/mednax-inc-md-receives-53-82-consensus-price-target-from-brokerages.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.